Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company specializing in oral therapies for neurologic diseases, has announced a 1-for-10 reverse stock split. The change will take effect at 12:01 a.m. Eastern Time on April 27, 2026. Post-split, Immunic's common stock will continue trading under the symbol "IMUX" on the Nasdaq Capital Market.

The decision, made during a special stockholders' meeting on April 14, aims to fulfill contractual obligations. The reverse stock split will reduce shares from approximately 136 million to about 13.6 million. It does not affect the number of authorized shares or the par value.

Fractional shares resulting from the split will be sold on the open market, and affected stockholders will receive proportional cash payments. Detailed information is available in the company's proxy statement filed with the SEC.